Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine
暂无分享,去创建一个
C. Mecucci | R. la Starza | R. Bassan | G. Roti | L. Pagliaro | M. Leoncin
[1] D. O’Connor,et al. Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia. , 2022, Blood.
[2] R. la Starza,et al. Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets , 2022, Cancers.
[3] A. Letai. Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens. , 2022, Cancer Discovery.
[4] O. Kallioniemi,et al. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma , 2021, Translational oncology.
[5] A. Moorman,et al. First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006) , 2021, Blood.
[6] J. Dipersio,et al. A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) , 2021, Blood.
[7] C. Mecucci,et al. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness , 2021, Genes.
[8] M. Loh,et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. , 2021, Cancer discovery.
[9] F. Lussana,et al. MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL , 2021, Cancers.
[10] S. Aerts,et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia. , 2021, Blood.
[11] M. Konopleva,et al. Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine , 2021, American journal of hematology.
[12] Chunxu Qu,et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. , 2021, Cancer discovery.
[13] G. Roti,et al. Targeting oncogenic Notch signaling with SERCA inhibitors , 2021, Journal of Hematology & Oncology.
[14] M. Loh,et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Fanin,et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study , 2020, American journal of hematology.
[16] E. Cencini,et al. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia , 2020, Clinical case reports.
[17] M. Konopleva,et al. Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma , 2020, American journal of hematology.
[18] N. Viiala,et al. Relapsed/Refractory ETP-ALL Successfully Treated With Venetoclax and Nelarabine as a Bridge to Allogeneic Stem Cell Transplant , 2020, HemaSphere.
[19] W. Stock,et al. Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults , 2020, Current Treatment Options in Oncology.
[20] K. Stegmaier,et al. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia. , 2020, Cell chemical biology.
[21] O. Heidenreich,et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia , 2020, Haematologica.
[22] R. Foà,et al. Design of a comprehensive fluorescence in situ hybridization assay for genetic classification of T-cell acute lymphoblastic leukemia. , 2020, The Journal of molecular diagnostics : JMD.
[23] C. Mecucci,et al. Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma. , 2020, Blood.
[24] L. Osnes,et al. T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol , 2019, Leukemia.
[25] M. Konopleva,et al. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. , 2019, Clinical lymphoma, myeloma & leukemia.
[26] C. Mecucci,et al. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia , 2019, JCO precision oncology.
[27] Zhiqiang Wu,et al. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells. , 2019, Journal of genetics and genomics = Yi chuan xue bao.
[28] M. Toribio,et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. , 2019, Blood.
[29] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[30] C. McMahon,et al. Relapsed T Cell ALL: Current Approaches and New Directions , 2019, Current Hematologic Malignancy Reports.
[31] C. Pui,et al. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. , 2019, The Lancet. Oncology.
[32] P. Van Vlierberghe,et al. A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia , 2018, Cells.
[33] S. Chiaretti,et al. New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Julie M Gastier-Foster,et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Klapper,et al. Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma , 2018, Haematologica.
[36] A. Look,et al. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells , 2018, Leukemia.
[37] M. Loh,et al. Genetic characterization and therapeutic targeting of MYC‐rearranged T cell acute lymphoblastic leukaemia , 2018, British journal of haematology.
[38] Traci M. Blonquist,et al. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia , 2018, The Journal of experimental medicine.
[39] P. Nuciforo,et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. , 2018 .
[40] Lieping Chen,et al. B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction , 2018, Proceedings of the National Academy of Sciences.
[41] M. Loh,et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.
[42] Bing Wang,et al. An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies , 2018, Leukemia.
[43] R. Foà,et al. High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement , 2018, Leukemia.
[44] J. Soulier,et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. , 2018, Blood.
[45] S. Aerts,et al. Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system , 2017, Leukemia.
[46] M. Piris,et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies , 2017, Nature Medicine.
[47] Li Zhang,et al. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: A case report , 2017, Experimental and therapeutic medicine.
[48] Ciaran M. Lee,et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. , 2017, Blood.
[49] Cheng Cheng,et al. THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA , 2017, Nature Genetics.
[50] H. Dombret,et al. Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] H. Dombret,et al. Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia , 2017, Leukemia.
[52] J. Taunton,et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias , 2017, Leukemia.
[53] David Tamborero,et al. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing , 2017, Oncotarget.
[54] Shana O Kelley,et al. New Technologies for Rapid Bacterial Identification and Antibiotic Resistance Profiling , 2017, SLAS technology.
[55] J. Aster,et al. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset , 2017, Oncotarget.
[56] Sebastian Uhrig,et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. , 2017, Blood.
[57] J. Cools,et al. The genetics and molecular biology of T-ALL. , 2017, Blood.
[58] Andrew P. Stubbs,et al. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study , 2016, PLoS medicine.
[59] A. Ferrando,et al. The genetics and mechanisms of T cell acute lymphoblastic leukaemia , 2016, Nature Reviews Cancer.
[60] H. Dombret,et al. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study , 2016, Haematologica.
[61] M. Loh,et al. Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study , 2015 .
[62] Hinrich W. H. Göhlmann,et al. Understanding drugs in breast cancer through drug sensitivity screening , 2015, SpringerPlus.
[63] J. Soulier,et al. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia , 2015, Haematologica.
[64] F. Kuo,et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma , 2015, Blood Cancer Journal.
[65] M. Brenner,et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. , 2015, Blood.
[66] C. Reynolds,et al. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235 , 2015, Clinical Cancer Research.
[67] N. Schork. Personalized medicine: Time for one-person trials , 2015, Nature.
[68] M. Loh,et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. , 2015, Blood.
[69] K. Baggerly,et al. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia , 2015, Clinical Cancer Research.
[70] F. Speleman,et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. , 2014, Blood.
[71] H. Dombret,et al. The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial , 2014 .
[72] S. Chiaretti,et al. Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. , 2014, Blood.
[73] A. Letai,et al. Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts , 2014, Clinical Cancer Research.
[74] M. Loh,et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.
[75] J. Cayuela,et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.
[76] O. Lohi,et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia , 2014, Leukemia.
[77] Andrea Califano,et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. , 2013, Cancer cell.
[78] A. Ferrando,et al. Early T-cell precursor acute lymphoblastic leukaemia , 2013, Current opinion in hematology.
[79] C. Mecucci,et al. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. , 2013, Blood.
[80] N. Perrimon,et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. , 2013, Cancer cell.
[81] J. McCubrey,et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia , 2012, Leukemia.
[82] J. Soulier,et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. , 2012, Cancer cell.
[83] A. Ferrando,et al. Targeting nonclassical oncogenes for therapy in T-ALL. , 2012, Cancer cell.
[84] A. Glass,et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. , 2012, Anticancer research.
[85] Kiran C. Bobba,et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.
[86] A. Ferrando,et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia , 2011, Nature Genetics.
[87] J. O'Reilly,et al. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse. , 2011, Leukemia research.
[88] Andrew P. Stubbs,et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. , 2011, Cancer cell.
[89] D. Hoelzer,et al. Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Andrea Califano,et al. The TLX1 oncogene drives aneuploidy in T-cell transformation , 2010, Nature Medicine.
[91] A. Ferrando,et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia , 2009, Nature Genetics.
[92] M. Muckenthaler,et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. , 2009, Blood.
[93] Raphael Kopan,et al. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. , 2009, Cancer cell.
[94] J. McCubrey,et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. , 2009, Cancer research.
[95] H. Beverloo,et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia , 2009, Leukemia.
[96] R. Pieters,et al. Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.
[97] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[98] Andrew P. Stubbs,et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. , 2007, Blood.
[99] Cheng Cheng,et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. , 2006, Blood.
[100] F. Speleman,et al. HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation , 2006, Leukemia.
[101] E. Macintyre,et al. Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. , 2004, Blood.
[102] Francois Pognan,et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.
[103] A. Ferrando,et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia , 2004, Nature Genetics.
[104] F. Speleman,et al. t(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH) , 2003, Leukemia.
[105] J. Zucman‐Rossi,et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. , 2002, Blood.
[106] E. Lander,et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.
[107] J. Ritz,et al. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. , 1992, Blood.
[108] A. Hagemeijer,et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia , 2009, Leukemia.